Biotechnology News

Biotechnology News – including medical research, studies, human genome, bio-technology devices and services news, as issued by the Send2Press Newswire service.


Microcide Announces Launch of Speed-breaker for Fast Moving COVID-19 Infections for Health Care Facilities

STERLING HEIGHTS, Mich., Jan. 4, 2021 (SEND2PRESS NEWSWIRE) — Microcide® Inc. a leading Michigan based biotechnology company, today announced the test results of its COVID-19 faster virus killing range of products, PRO-SAN® Cleaner sanitizer, SILKY-SOFT® hand sanitizer, and DENTORAL® mouthwash.

Synthetic Biology for Tennessee Schools: BioBuilder Partners with Niswonger Foundation on $8.8M Federal Grant for STEM Education

CAMBRIDGE, Mass., Dec. 29, 2020 (SEND2PRESS NEWSWIRE) — The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an “Education Innovation and Research” (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM).

Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers

OKLAHOMA CITY, Okla. and AUSTIN, Texas, Nov. 30, 2020 (SEND2PRESS NEWSWIRE) — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website.

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va., Oct. 28, 2020 (SEND2PRESS NEWSWIRE) — Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif., Oct. 26, 2020 (SEND2PRESS NEWSWIRE) — The American College of Gastroenterology (ACG) named Progenabiome “Outstanding Poster Presenter” for its poster: “Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection,” which will be presented virtually at the ACG Annual Scientific Meeting this week.

Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting

OKLAHOMA CITY, Okla. and AUSTIN, Texas, Oct. 15, 2020 (SEND2PRESS NEWSWIRE) — Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 – 21, 2020.

Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery

STONY BROOK, N.Y., July 20, 2020 (SEND2PRESS NEWSWIRE) — Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif., April 2, 2020 (SEND2PRESS NEWSWIRE) — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

Lyme Disease Biobank Expands Into San Diego

SAN DIEGO, Calif., March 6, 2020 (SEND2PRESS NEWSWIRE) — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation’s Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y., Nov. 14, 2019 (SEND2PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

Hans van der Sluijs Joins BioTork as Chief Development Officer

GAINESVILLE, Fla., Oct. 30, 2019 (SEND2PRESS NEWSWIRE) — BioTork, the leading evolution biotechnology company, today announced that biotech executive Hans van der Sluijs has joined the company as Chief Development Officer. Hans brings over 20 years of international business leadership experience, with a focus on business development, management, and building strategic alliances/partnerships.

Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif., Oct. 8, 2019 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Brandon Stem Cell Clinic Offers Life-changing Treatment Options

TAMPA, Fla., Aug. 12, 2019 (SEND2PRESS NEWSWIRE) — Brandon Stem Cell Clinic (BSCC) recognizes that osteoarthritis is one of the most common joint conditions, affecting nearly 630 million people worldwide. It is commonly associated with aging but is also frequently seen in cases of overuse of joints. The growing number of cases alone prove a need for innovative and effective treatments as populations continue to age. (VIDEO)

New Market Research Report on Bioelectronic Medicine Forecasts $16.6B Market

SAN FRANCISCO, Calif., May 9, 2019 (SEND2PRESS NEWSWIRE) — A newly published market research report from Neurotech Reports, the leading market intelligence firm in the neurotechnology industry, forecasts that the worldwide market for bioelectronic medicine and related technologies will reach $16.6 billion by 2025.

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla., Feb. 21, 2019 (SEND2PRESS NEWSWIRE) — The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Sue Siegel to Keynote 2019 Bioelectronic Medicine Forum in NY

NEW YORK, N.Y., Feb. 20, 2019 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announces that Sue Siegel, Chief Innovation Officer at GE and CEO of GE Ventures, will keynote the 2019 Bioelectronic Medicine Forum, which takes place in New York City on April 4, 2019.

Neurotech Reports Announces 2018 Investment and Management Conference for Bioelectronic Medicine

NEW YORK, N.Y., Jan. 30, 2018 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Iron Dust from Brakes and Worldwide Magnesium Deficiencies are Contributing to Hypertension

KESWICK, Va., Nov. 14, 2017 (SEND2PRESS NEWSWIRE) — With 25 years of research involving primarily the cardiovascular complications of spaceflight and more recently of the moon walkers, particularly Neil Armstrong on his historic mission and James Irwin (Apollo 15), extraordinary findings were discovered. Both had vascular complications, triggered by inhalation of deadly iron-laden dust. Author Dr. William J. Rowe has applied this information as to how this can be utilized for underlying mechanisms of hypertension on earth, triggered by iron-laden brake dust.

ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection

SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

Medical Experts Unite Regarding Health Benefits of Testosterone Therapy in Women

IRVING, Texas, April 19, 2017 (SEND2PRESS NEWSWIRE) – BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

Solesence and Colorescience Announce Skin Care Collaboration

ROMEOVILLE, Ill., Jan. 31, 2017 (SEND2PRESS NEWSWIRE) — Solesence, a skin care product manufacturer at the forefront of environmental protection technology, has announced a partnership with leading prestige beauty brand Colorescience in a special collaboration to develop products for skin care and protection. As part of their joint development and supply relationship, Solesence will use patented mineral skin care actives technology to develop sunscreen products exclusively for Colorescience.

Key Startups and Industry Figures to Present at 2016 Neurotech Leaders Forum

SAN FRANCISCO, Calif., Oct. 10, 2016 (SEND2PRESS NEWSWIRE) — Several promising neurotechnology firms and key industry figures will present at the 2016 Neurotech Leaders Forum. The 16th annual event will take place October 24-25 in San Francisco, presented by Neurotech Reports. Keynote speaker at this year’s event on October 24 will be Doug Weber, who serves as program manager for DARPA’s Biological Technologies Office.

Paragon BioTeck to Attend 34th Annual J.P. Morgan Healthcare Conference

PORTLAND, Ore., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.

Thanksgiving Promotion at Creative Animodel

SHIRLEY, N.Y., Nov. 25, 2015 (SEND2PRESS NEWSWIRE) — Thanksgiving Day will come tomorrow, and Creative Animodel will welcome its eighth Thanksgiving Day. For eight years, Creative Animodel has been sincere in its service to its customers. On the occasion of the arrival of Thanksgiving Day, Creative Animodel will offer a great Thanksgiving promotion, as a way to thank all its supporters.

MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the ‘Company’ / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.

MEDITE Cancer Diagnostics, Inc. Reports Second Quarter and Six Month 2015 Results

ORLANDO, Fla., Aug. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: MDIT / OTCBB:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.

Stem Cell ARTS’ Dr. Mayo Friedlis Invited to Lecture in China on Regenerative Injection Therapy in Treating Musculoskeletal Pain

MCLEAN, Va., July 6, 2015 (SEND2PRESS NEWSWIRE) — StemCell ARTS, an affiliate of National Spine and Pain Centers, is proud to announce that Dr. Mayo Friedlis was invited to co-lead the esteemed ‘CUHK Primary Care Symposium 2015’ on July 4, 2015 in Hong Kong, N.T., People’s Republic of China. Dr. Friedlis presented a Plenary Lecture on ‘Musculoskeletal Intervention of Primary Care Physicians: The Role on Injection Therapy.’

Release and Book Signing of BioTE Medical President Gary Donovitz M.D. ‘Age Healthier Live Happier’ at Age Management Medicine Group (AMMG) Conference

ORLANDO, Fla., April 23, 2015 (SEND2PRESS NEWSWIRE) — BioTE Medical President and Founder Gary Donovitz M.D. releases his book ‘Age Healthier Live Happier – Avoiding Over-Medication through Natural Hormone Balance’ (ISBN: 9780990706458) to kick off the Age Management Medicine Group Conference at JW Marriott / Ritz Carlton Grande Lakes April 23 – 26, 2015.

Reaction Biology Launches Recombinant Methyltransferase Line

MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine – Treatments Not Yet Offered in U.S.

KIRKLAND, Wash. (SEND2PRESS NEWSWIRE) — Many Americans – unsatisfied with traditional treatments for cancer, diabetes, osteoporosis, and other intractable diseases – are looking south for advanced remedies. ‘We’re struggling to keep up with demand,’ says Dr. Oscar E. Castro, head of Regenerative Cellular Therapy (RCT), of Puerto Penasco, Sonora, Mexico.

To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.

Lower Back Pain is Targeted by LifeModeler, Inc. with Newly Released Software

SAN CLEMENTE, Calif. (SEND2PRESS NEWSWIRE) — LifeModeler, Inc., the leading global provider of biomechanical human body simulation tools and services, has released LumbarSIM™, a new product that adds to its family of unique ‘virtual prototyping’ software. This latest innovation directly addresses the needs of orthopedic device manufacturers and surgeons seeking ways to respond to the growing numbers of patients experiencing lower back pain.

FDA Grants Epeius Biotechnologies’ Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas

SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indication for which Rexin-G has been formally recognized by the FDA in the United States.

California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System

SAN MARINO, Calif. – July 10 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world’s first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers.

Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation

PASADENA, Calif. – June 18 (SEND2PRESS NEWSWIRE) — Osmetech plc (LSE, AIM; OMH) today announced that it has granted a non-exclusive research license to Waltham, Massachusetts, US-based Minerva Biotechnologies Corporation (‘Minerva’) for use of Osmetech’s self-assembling monolayer (SAM) technology in conjunction with Minerva’s proprietary nanoparticle technology.

Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc.

FRESNO, Calif. – June 13 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has hired Mark Whitacre, Ph.D. Dr. Whitacre joined the executive management team effective January 1, 2007 as COO & President, Technology and Business Development, following the opening of a new office in Pensacola, Florida in December, 2006.

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences

SAN MARINO, Calif. – May 15 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company’s innovative tumor-targeting technology embodied in its lead product, Rexin-G.

Rexin-G(TM), The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer

SAN MARINO, Calif. and MANILA, Philippines – Nov. 6 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.

Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine

SAN MARINO, Calif. – Oct. 11 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company’s innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).